Research programme: monoclonal antibody immunoconjugates - Valor Biotherapeutics

Drug Profile

Research programme: monoclonal antibody immunoconjugates - Valor Biotherapeutics

Alternative Names: CmAbs; IGN 001; IGN 003; mAb-IFN fusion protein therapeutics - Valor Biotherapeutics; mAb-IFN therapeutics - ImmunGene/Valor Biotherapeutics; Monoclonal antibody fusion proteins - ImmunGene/Caliber Biotherapeutics/Valor Biotherapeutics

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator ImmunGene
  • Developer Valor Biotherapeutics
  • Class Immunoconjugates; Monoclonal antibodies; Proteins
  • Mechanism of Action Apoptosis stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Multiple myeloma
  • Research Cancer

Most Recent Events

  • 02 May 2017 Early research development for Cancer is ongoing in USA, before May 2017
  • 02 May 2017 ImmunGene acquires IGN 001 and IGN 003 from Valor Biotherapeutics
  • 02 May 2017 Preclinical trials in Breast cancer in USA (Parenteral), before May 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top